33

The Investigators · The Reporter · The Mole

2017 . . . Adding up the winnings . . . Conspiracies abound . . . Klaussen reaches out . . . A meeting in Hanoi . . . The Mastermind's fate

T he next time I saw Kent Bailey in Minneapolis, six months after the RX Limited trial, he sounded surprisingly sanguine about the verdict. He was furious at his own prosecutors for their mistakes, but he seemed to have long resigned himself to disap- pointment, after he and Brill lost the battle over Le Roux with the SOD's 960 group back in 2012. He still believed Moran Oz and the rest of the RX Limited operators deserved to go to prison. "The bottom line is that the reason that Kim started on this case was that we knew that they were causing harm in the United States," he said. "They were using our infrastructure to cause harm to our citizens." Even with the acquittals, dozens of people serving as nodes on the network had faced varying punishments for their in- volvement in RX Limited: doctors, pharmacists, and operators like Jon Wall who had pleaded guilty in cases from Detroit to Newark to Texas.

Bailey's outlook, in a way, aligned with that of Oz and McCon- nell's defense attorneys: Le Roux had been the prize, the one man that didn't warrant a deal. "I'm 100 percent convinced that we are